Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review

References

• OECD. Addressing challenges in access to oncology medicines. Paris: OECD; 2020.
   Google Scholar
• Park J, Look KA. Health care expenditure burden of cancer care in the United States. Inquiry. 2019;56:46958019880696.
   PubMed Web of Science ®Google Scholar
• IQVIA. Global oncology trends 2019. USA. 2019.
   Google Scholar
• Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst. 1993;85:1460–1474.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Earle C, Fang CH, et al. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82–88.
   PubMed Web of Science ®Google Scholar
• Winn AN, Ekwueme DU, Guy GP Jr, et al. Cost-utility analysis of cancer prevention, treatment, and control: a systematic review. Am J Prev Med. 2016;50(2):241–248.
   PubMed Web of Science ®Google Scholar
• Bridges JF. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2003;2(4):213–224.
   PubMedGoogle Scholar
• Havet N, Morelle M, Remonnay R, et al. Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network. Eur J Health Econ. 2012;13(3):289–300.
   PubMed Web of Science ®Google Scholar
• Olsen JA, Smith RD. Theory versus practice: a review of ‘willingness-to-pay’ in health and health care. Health Econ. 2001;10(1):39–52.
   PubMed Web of Science ®Google Scholar
• Lin PJ, Cangelosi MJ, Lee DW, et al. Willingness to pay for diagnostic technologies: a review of the contingent valuation literature. Value Health. 2013;16(5):797–805.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programme. Fourth ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• Bayoumi AM. The measurement of contingent valuation for health economics. PharmacoEconomics. 2004;22(11):691–700.
   PubMed Web of Science ®Google Scholar
• Klose T. The contingent valuation method in health care. Health Policy. 1999;47(2):97–123.
   PubMed Web of Science ®Google Scholar
• Lang H-C. Willingness to pay for lung cancer treatment. Value Health. 2010;13(6):743–749.
   PubMed Web of Science ®Google Scholar
• Soekhai V, de Bekker-Grob EW, Ellis AR, et al. Discrete choice experiments in health economics: past, present and future. PharmacoEconomics. 2019;37(2):201–226.
   PubMed Web of Science ®Google Scholar
• Wolff E, Larsson S, Svensson M. Willingness to pay for health improvements Using Stated Preferences: prevention Versus Treatment. Value Health. 2020;23(10):1384–1390.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Oanda currency converter.
   Google Scholar
• Dranitsaris G. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? Int J Technol Assess Health Care. 1999;15(1):108–122.
   PubMed Web of Science ®Google Scholar
• Weston A, Fitzgerald P. Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. PharmacoEconomics. 2004;22(18):1195–1208.
   PubMed Web of Science ®Google Scholar
• Aristides M, Chen J, Schulz M, et al. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer. PharmacoEconomics. 2002;20(11):775–784.
   PubMed Web of Science ®Google Scholar
• Ho W, Broughton DE, Donelan K, et al. Analysis of barriers to and patients‘ preferences for CT colonography for colorectal cancer screening in a nonadherent Urban population. AJR. 2010;195(2):393–397.
   PubMed Web of Science ®Google Scholar
• Essers BA, Dirksen CD, Prins MH, et al. Assessing the public’s preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands. Dermatologic Surg. 2010;36(12):1950–1955.
   PubMed Web of Science ®Google Scholar
• Gardino SL, Sfekas A, Dranove D. Anticipating ovarian tissue cryopreservation in the health-care marketplace: a willingness to pay assessment. Cancer Treat Res. 2010;156:363–370.
   PubMedGoogle Scholar
• Tan Sean P, Chouaid C, Hettler D, et al. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. Curr Med Res Opin. 2009;25(6):1455–1460.
   PubMed Web of Science ®Google Scholar
• Marshall DA, Johnson FR, Kulin NA, et al. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ. 2009;18(12):1420–1439.
   PubMed Web of Science ®Google Scholar
• Ian J, Bateman R. Consistency and construction in stated WTP for health risk reductions: a novel scope-sensitivity test. Resour Energy Econ. 2006;28(3):199–214.
   Web of Science ®Google Scholar
• Qureshi AA, Brandling-Bennett HA, Wittenberg E, et al. Willingness-to-pay stated preferences for telemedicine versus in-person visits in patients with a history of psoriasis or melanoma. Telemed J E Health. 2006;12(6):639–643.
   PubMed Web of Science ®Google Scholar
• Lalla D, Carlton R, Santos E, et al. Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis. SpringerPlus. 2014;3(1):350.
   PubMedGoogle Scholar
• Greenberg D, Hammerman A, Vinker S, et al. Which is more valuable, longer survival or better quality of life? Israeli oncologists’ and family physicians’ attitudes toward the relative value of new cancer and congestive heart failure interventions. Value Health. 2013;16(5):842–847.
   PubMed Web of Science ®Google Scholar
• Thiel FC, Scharl A, Hildebrandt T, et al. Financing of certified centers: a willingness-to-pay analysis. Arch Gynecol Obstet. 2013;287(3):495–509.
   PubMed Web of Science ®Google Scholar
• Ethier MC, Regier DA, Tomlinson D, et al. Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer. Support Care Cancer. 2012;20(8):1771–1777.
   PubMed Web of Science ®Google Scholar
• Belkora J, Stupar L, O’Donnell S, et al. Decision support by telephone: randomized controlled trial in a rural community setting. Patient Educ Couns. 2012;89(1):134–142.
   PubMed Web of Science ®Google Scholar
• Teuffel O, Cheng S, Ethier MC, et al. Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer. 2012;20(11):2755–2764.
   PubMed Web of Science ®Google Scholar
• Regier DA, Diorio C, Ethier MC, et al. Discrete choice experiment to evaluate factors that influence preferences for antibiotic prophylaxis in pediatric oncology. PloS one. 2012;7(10):e47470.
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Iyer S, Librach SL, et al. Methylnaltrexone in the treatment of opioid-induced constipation in cancer patients receiving palliative care: willingness-to-pay and cost-benefit analysis. J Pain Symptom Manage. 2011;41(1):104–115.
   PubMed Web of Science ®Google Scholar
• Spinks J, Janda M, Soyer HP, et al. Consumer preferences for teledermoscopy screening to detect melanoma early. J Telemed Telecare. 2016;22(1):39–46.
   PubMed Web of Science ®Google Scholar
• Snoswell CL, Whitty JA, Caffery LJ, et al. Direct-to-consumer mobile teledermoscopy for skin cancer screening: preliminary results demonstrating willingness-to-pay in Australia. J Telemed Telecare. 2018;24(10):683–689.
   PubMed Web of Science ®Google Scholar
• Olofsson S, Gerdtham UG, Hultkrantz L, et al. Measuring the end-of-life premium in cancer using individual ex ante willingness to pay. Eur J Health Econ. 2018;19(6):807–820.
   PubMed Web of Science ®Google Scholar
• Vass CM, Rigby D, Payne K. Investigating the heterogeneity in women’s preferences for breast screening: does the communication of risk matter? Value Health. 2018;21(2):219–228.
   PubMed Web of Science ®Google Scholar
• Weymann D, Veenstra DL, Jarvik GP, et al. Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment. Eur J Human Genet. 2018;26(9):1257–1265.
   PubMed Web of Science ®Google Scholar
• Bazarbashi S, De Vol EB, Maraiki F, et al. Empirical monetary valuation of a quality-adjusted life-year in the Kingdom of Saudi Arabia: a willingness-to-pay analysis. Pharmacoecon Open. 2020;4(4):625–633.
   PubMed Web of Science ®Google Scholar
• Dhanda DS, Veenstra DL, Regier DA, et al. Payer preferences and willingness to pay for genomic precision medicine: a discrete choice experiment. J Manag Care Spec Pharm. 2020;26(4):529–537.
   PubMed Web of Science ®Google Scholar
• Robles LA, Wright SJ, Hackshaw-McGeagh L, et al. Prostate cancer survivors’ preferences on the delivery of diet and lifestyle advice: a pilot best-worst discrete choice experiment. Pilot Feasibility Stud. 2020;6(1):2.
   PubMedGoogle Scholar
• Golda N, Black W, Patel V, et al. Determining patient preferences and willingness to pay related to scar length and appearance after skin cancer treatment on the face and trunk: a multicenter discrete choice experiment. J Am Acad Dermatol. 2019;81(4):1011–1013.
   PubMed Web of Science ®Google Scholar
• Iskrov G, Greenberg D, Yakimov I, et al. What Is the value of innovative pharmaceutical therapies in oncology and hematology? A Willingness-to-Pay Study in Bulgaria. Value Health Reg Issues. 2019;19:157–162.
   PubMedGoogle Scholar
• Saengow U, Birch S, Geater A, et al. Willingness to pay for colorectal cancer screening and effect of copayment in Southern Thailand. Asian Pac J Cancer Prev. 2018;19(6):1727–1734.
   PubMedGoogle Scholar
• Stenehjem DD, Au TH, Ngorsuraches S, et al. Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Melanoma Res. 2019;29(6):626–634.
   PubMed Web of Science ®Google Scholar
• Choi HC, Leung GM, Woo PP, et al. Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents. Vaccine. 2013;32(1):78–84.
   PubMed Web of Science ®Google Scholar
• Tarekegn AA, Mengistu MY, Mirach TH. Health professionals’ willingness to pay and associated factors for cervical cancer screening program at College of medicine and health sciences, University of Gondar, Northwest Ethiopia. PloS one. 2019;14(4):e0215904.
   PubMed Web of Science ®Google Scholar
• Tarekegn AA, Yismaw AE. Health professionals’ willingness to pay and associated factors for human papilloma virus vaccination to prevent cervical cancer at College of Medicine and Health Sciences University of Gondar, Northwest Ethiopia. BMC Res Notes. 2019;12(1):58.
   PubMedGoogle Scholar
• Johnson P, Bancroft T, Barron R, et al. Discrete choice experiment to estimate breast cancer patients’ preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. Value Health. 2014;17(4):380–389.
   PubMed Web of Science ®Google Scholar
• Brown DS, Poulos C, Johnson FR, et al. Adolescent girls’ preferences for HPV vaccines: a discrete choice experiment. Adv in Health Econ and Health Serv Res. 2014;24:93–121.
   PubMedGoogle Scholar
• Raghavendra M. Patient interest in video recording of colonoscopy: a survey. World J Gastroenterol. 2010;16(4):458–461.
   PubMed Web of Science ®Google Scholar
• Jan MS, Fu TT, Huang CL. Willingness to pay for low-lung-cancer-risk cigarettes in Taiwan. Health Econ. 2005;14:55–67.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Elia-Pacitti J, Cottrell W. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. PharmacoEconomics. 2004;22(6):375–387.
   PubMed Web of Science ®Google Scholar
• Raab SS, Grzybicki DM, Hart AR, et al. Willingness to pay for new Papanicolaou test technologies. Am J Clin Pathol. 2002;117(4):524–533.
   PubMed Web of Science ®Google Scholar
• Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer. 1998;83(12):2588–2596.
   PubMed Web of Science ®Google Scholar
• Havet N, Morelle M, Remonnay R, et al. Valuing the benefit for cancer patients of receiving blood transfusions at home. J Benefit-Cost Anal. 2011;2(3):1–19.
   Google Scholar
• Hammitt JK, Haninger K. Valuing fatal risks to children and adults: effects of disease, latency, and risk aversion. J Risk Uncertainty. 2010;40(1):57–83.
   Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Hammitt JK, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ. 2012;21(3):238–251.
   PubMed Web of Science ®Google Scholar
• Yasunaga H, Sugihara T, Imamura T. Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: a contingent valuation survey. Urology. 2011;77(6):1325–1329.
   PubMed Web of Science ®Google Scholar
• Milligan MA, Bohara AK, Pagán JA. Assessing willingness to pay for cancer prevention. Int J Health Care Finance Econ. 2010;10(4):301–314.
   PubMedGoogle Scholar
• Yasunaga H, Ide H, Imamura T, et al. Benefit evaluation of mass screening for prostate cancer: willingness-to-pay measurement using contingent valuation. Urology. 2006;68(5):1046–1050.
   PubMed Web of Science ®Google Scholar
• Franic DM, Pathak DS, Gafni A. Quality-adjusted life years was a poor predictor of women’s willingness to pay in acute and chronic conditions: results of a survey. J Clin Epidemiol. 2005;58(3):291–303.
   PubMed Web of Science ®Google Scholar
• Kaul S, Smits-Seemann RR, Zamora ER, et al. Adolescent and young adult cancer survivors’ valuation of post-treatment recommended care. J Adolesc Young Adult Oncol. 2017;6(1):127–133.
   PubMed Web of Science ®Google Scholar
• Wong SF, Norman R, Dunning TL, et al. A discrete choice experiment to examine the preferences of patients with cancer and their willingness to pay for different types of health care appointments. J Natl Compr Canc Netw. 2016;14(3):311–319.
   PubMed Web of Science ®Google Scholar
• Ngorsuraches S, Nawanukool K, Petcharamanee K, et al. Parents’ preferences and willingness-to-pay for human papilloma virus vaccines in Thailand. J Pharm Policy Pract. 2015;8(1):20.
   PubMedGoogle Scholar
• Wright SJ, Gibson D, Eden M, et al. What are colorectal cancer survivors’ preferences for dietary advice? A best-worst discrete choice experiment. J Cancer Surviv. 2017;11(6):782–790.
   PubMed Web of Science ®Google Scholar
• Bernard M, Brignone M, Adehossi A, et al. Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study. Lung Cancer. 2011;72(1):114–118.
   PubMed Web of Science ®Google Scholar
• Butow P, Davies G, Napier CE, et al. Assessment of the value of tumor variation profiling perceived by patients with cancer. JAMA network open. 2020;3(5):e204721.
   PubMed Web of Science ®Google Scholar
• Li C, Zeliadt SB, Hall IJ, et al. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012;15(5):716–723.
   PubMed Web of Science ®Google Scholar
• Wagner TH, Hu T, Dueñas GV, et al. Does willingness to pay vary by race/ethnicity? An analysis using mammography among low-income women. Health Policy. 2001;58(3):275–288.
   PubMed Web of Science ®Google Scholar
• Brown DS, Johnson FR, Poulos C, et al. Mothers’ preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010;28(7):1702–1708.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Russell LB, Chou J, et al. Willingness-to-pay to avoid the time spent and discomfort associated with screening colonoscopy. Health Econ. 2010;19(10):1193–1211.
   PubMed Web of Science ®Google Scholar
• Ha TV, Hoang MV, Vu MQ, et al. Willingness to pay for a quality-adjusted life year among advanced non-small cell lung cancer patients in Viet Nam, 2018. Medicine (Baltimore). 2020;99(9):e19379.
   PubMed Web of Science ®Google Scholar
• Lemos S, Halstead JM, Mohr RD, et al. Valuing the cancer mortality risk reduction from lowering the arsenic maximum contaminant level in new hampshire municipal water supplies. Environ Manage. 2020;65(6):725–736.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Blonquist TM, Hong F, et al. Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis. BMC Med Inform Decis Mak. 2019;19(1):6.
   PubMedGoogle Scholar
• Augustin M, Blome C, Forschner A, et al. Willingness to pay for a cure of low-risk melanoma patients in Germany. PloS one. 2018;13(5):e0197780.
   PubMed Web of Science ®Google Scholar
• Alberini A, Ščasný M. The benefits of avoiding cancer (or dying from cancer): evidence from a four- country study. J Health Econ. 2018;57:249–262.
   PubMed Web of Science ®Google Scholar
• Mansfield C, Ekwueme DU, Tangka FKL, et al. Colorectal cancer screening: preferences, past behavior, and future intentions. Patient. 2018;11(6):599–611.
   PubMedGoogle Scholar
• Wong XY, Groothuis-Oudshoorn CG, Tan CS, et al. Women’s preferences, willingness-to-pay, and predicted uptake for single-nucleotide polymorphism gene testing to guide personalized breast cancer screening strategies: a discrete choice experiment. Patient Prefer Adherence. 2018;12:1837–1852.
   PubMed Web of Science ®Google Scholar
• Wong CKH, Man KKC, Ip P, et al. Mothers’ preferences and willingness to pay for human papillomavirus vaccination for their daughters: a discrete choice experiment in Hong Kong. Value Health. 2018;21(5):622–629.
   PubMed Web of Science ®Google Scholar
• Hollinghurst S, Banks J, Bigwood L, et al. Using willingness-to-pay to establish patient preferences for cancer testing in primary care. BMC Med Inform Decis Mak. 2016;16(1):105.
   PubMed Web of Science ®Google Scholar
• Finkelstein E, Malhotra C, Chay J, et al. Impact of treatment subsidies and cash payouts on treatment choices at the end of life. Value Health. 2016;19(6):788–794.
   PubMed Web of Science ®Google Scholar
• Cuffe S, Hon H, Qiu X, et al. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. Pharmacogenet Genomics. 2014;24(7):348–355.
   PubMed Web of Science ®Google Scholar
• Cerda AA, Garcia LY, Gaete FI, et al. [Willingness to pay for human papillomavirus vaccine in Metropolitan Santiago, Chile]. Revista medica de Chile. 2013;141(2):167–172.
   PubMed Web of Science ®Google Scholar
• Yasunaga H. Who wants cancer screening with PET? A contingent valuation survey in Japan. Eur J Radiol. 2009;70(1):190–194.
   PubMed Web of Science ®Google Scholar
• Yasunaga H. Willingness to pay for mass screening for prostate cancer: a contingent valuation survey. Int J Urol. 2008;15(1):102–105. discussion 05.
   PubMed Web of Science ®Google Scholar
• Van Bebber SL, Liang SY, Phillips KA, et al. Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Per Med. 2007;4(3):341–350.
   PubMed Web of Science ®Google Scholar
• Yasunaga H, Ide H, Imamura T, et al. The measurement of willingness to pay for mass cancer screening with whole-body PET (positron emission tomography). Ann Nucl Med. 2006;20(7):457–462.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Leung P, Ciotti R, et al. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. PharmacoEconomics. 2001;19(9):955–967.
   PubMed Web of Science ®Google Scholar
• Wordsworth S, Ryan M, Waugh N. Costs and benefits of cervical screening IV: valuation by women of the cervical screening programme. Cytopathol: Official J of the British Soc for Clini Cytol. 2001;12(6):367–376.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Support Care Cancer. 1997;5(6):489–499.
   PubMed Web of Science ®Google Scholar
• Davidson BA, Ehrisman J, Reed SD, et al. Preferences of women with epithelial ovarian cancer for aspects of genetic testing. Gynecol Oncol Res Pract. 2019;6(1):1.
   PubMedGoogle Scholar
• Protière C, Chanel O, Nogues C, et al. How can contingent valuation inform the bioethics debate? Evidence from a survey on hereditary cancers in France. Revue économique. 2017;68(3):379–404.
   Google Scholar
• Sabermahani A, Mohammad Taghizade S, Goodarzi R, et al. Study on willingness to pay for breast cancer and osteoporosis screening in Kerman, Southeastern Iran. Iran J Public Health. 2017;46(5):693–698.
   PubMed Web of Science ®Google Scholar
• Oh DY, Crawford B, Kim SB, et al. Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study. Asia Pac J Clin Oncol. 2012;8(3):282–291.
   PubMed Web of Science ®Google Scholar
• Lang HC, Chang K, Ying YH. Quality of life, treatments, and patients’ willingness to pay for a complete remission of cervical cancer in Taiwan. Health Econ. 2012;21(10):1217–1233.
   PubMed Web of Science ®Google Scholar
• Wang H, He J. Estimating the economic value of statistical life in china: a study of the willingness to pay for cancer prevention. Front Econ China. 2014;9:183–215.
   Google Scholar
• Zhu S, Chang J, Hayat K, et al. Parental preferences for HPV vaccination in junior middle school girls in China: a discrete choice experiment. Vaccine. 2020;38(52):8310–8317.
   PubMed Web of Science ®Google Scholar
• Rajiah K, Maharajan MK, Fang Num KS, et al. Knowledge about human papillomavirus and cervical cancer: predictors of HPV Vaccination among Dental Students. Asian Pac J Cancer Prev. 2017;18(6):1573–1579.
   PubMedGoogle Scholar
• Umeh IB, Nduka SO, Ekwunife OI. Mothers’ willingness to pay for HPV vaccines in Anambra state, Nigeria: a cross sectional contingent valuation study. Cost Eff and Res Allocation: C/E. 2016;14(1):8.
   PubMedGoogle Scholar
• Miron-Shatz T, Hanoch Y, Doniger GM, et al. Subjective but not objective numeracy influences willingness to pay for BRCA1/2 genetic testing. Judgment and Decision making; 2014;9(2):152–158.
   Google Scholar
• Malhotra C, Farooqui MA, Kanesvaran R, et al. Comparison of preferences for end-of-life care among patients with advanced cancer and their caregivers: a discrete choice experiment. Palliat Med. 2015;29(9):842–850.
   PubMed Web of Science ®Google Scholar
• Ávila M, Becerra V, Guedea F, et al. Estimating preferences for treatments in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2015;91(2):277–287.
   PubMed Web of Science ®Google Scholar
• Ngorsuraches S, Thongkeaw K. Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments. SpringerPlus. 2015;4(1):674.
   PubMedGoogle Scholar
• Yasunaga H, Ide H, Imamura T, et al. Women’s anxieties caused by false positives in mammography screening: a contingent valuation survey. Breast Cancer Res Treat. 2007;101(1):59–64.
   PubMed Web of Science ®Google Scholar
• Fu -T-T, Liu J-T, Hammitt JK. Consumer willingness to pay for low-pesticide fresh produce in Taiwan. Journal of Agricultural Economics. 1999;50:220–233.
   Web of Science ®Google Scholar
• Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45(2–3):107–114.
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Bilger M, Flynn TN, et al. Preferences for end-of-life care among community-dwelling older adults and patients with advanced cancer: a discrete choice experiment. Health Policy. 2015;119(11):1482–1489.
   PubMed Web of Science ®Google Scholar
• Leighl NB, Tsao WS, Zawisza DL, et al. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2006;51(1):115–121.
   PubMed Web of Science ®Google Scholar
• Sun H, Wang H, Xu N, et al. Patient preferences for chemotherapy in the treatment of non-small cell lung cancer: a multicenter discrete choice experiment (DCE) Study In China. Patient Prefer Adherence. 2019;13:1701–1709.
   PubMed Web of Science ®Google Scholar
• Wordsworth S, Ryan M, Skåtun D, et al. Women’s preferences for cervical cancer screening: a study using a discrete choice experiment. Int J Technol Assess Health Care. 2006;22(3):344–350.
   PubMed Web of Science ®Google Scholar
• Oteng B, Marra F, Lynd LD, et al. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme. Sex Transm Infect. 2011;87(1):52–57.
   PubMed Web of Science ®Google Scholar
• Poulos C, Yang JC, Levin C, et al. Mothers’ preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Soc Sci Med. 2011;73(2):226–234.
   PubMed Web of Science ®Google Scholar
• Liao CH, Liu JT, Pwu RF, et al. Valuation of the economic benefits of human papillomavirus vaccine in Taiwan. Value Health. 2009;12(Suppl 3):S74–7.
   PubMedGoogle Scholar
• Turner HC, Archer RA, Downey LE, et al. An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations. Front Public Health. 2021;9:722927.
   PubMedGoogle Scholar
• Phelps CE. A new method to determine the optimal willingness to pay in cost-effectiveness analysis. Value Health. 2019;22(7):785–791.
   PubMed Web of Science ®Google Scholar
• Woods B, Revill P, Sculpher M, et al. Country-level Cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733–744.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• Rocchi A, Menon D, Verma S, et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008;11(4):771–783.
   PubMed Web of Science ®Google Scholar
• Baltussen R, Marsh K, Thokala P, et al. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward. Value Health. 2019;22(11):1283–1288.
   PubMed Web of Science ®Google Scholar
• McDougall JA, Furnback WE, Wang BCM, et al. Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy. 2020;8(1):1717030.
   PubMedGoogle Scholar
• Steigenberger C, Flatscher-Thoeni M, Siebert U, et al. Determinants of willingness to pay for health services: a systematic review of contingent valuation studies. Eur J Health Econ. 2022;23:1–28.
   PubMed Web of Science ®Google Scholar
• Husereau D. How do we value a cure? Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):551–555.
   PubMed Web of Science ®Google Scholar
• Khaliq W, Harris CM, Landis R, et al. Hospitalized women’s willingness to pay for an inpatient screening mammogram. Ann Fam Med. 2014;12(6):556–558.
   PubMed Web of Science ®Google Scholar
• Clarke PM. Testing the convergent validity of the contingent valuation and travel cost methods in valuing the benefits of health care. Health Econ. 2002;11(2):117–127.
   PubMed Web of Science ®Google Scholar
• Liang W, Lawrence WF, Burnett CB, et al. Acceptability of diagnostic tests for breast cancer. Breast Cancer Res Treat. 2003;79(2):199–206.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP Jr, et al. Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Ben-Aharon O, Magnezi R, Leshno M, et al. Association of immunotherapy with durable survival as defined by value frameworks for cancer care. JAMA Oncol. 2018;4(3):326–332.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016;34(24):2925–2934.
   PubMed Web of Science ®Google Scholar
• Schlander M. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process. J Med Ethics. 2008;34(7):534–539.
   PubMed Web of Science ®Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–930.
   PubMed Web of Science ®Google Scholar
• Wagner M, Samaha D, Casciano R, et al. Moving towards accountability for reasonableness - a systematic exploration of the features of legitimate healthcare coverage decision-making processes using rare diseases and regenerative therapies as a case study. Int J Health Policy Manag. 2019;8(7):424–443.
   PubMed Web of Science ®Google Scholar
• Takatsuka Y. Comparison of the contingent valuation method and the stated choice model for measuring benefits of ecosystem management: a case study of the Clinch River Valley, Tennessee. USA: University of Tennessee; 2004.
   Google Scholar